Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.93
Nov 17 • 8:04 AM ET Dollar change-0.09 Percentage change(-2.98%)
Index
-
Market Cap
510.23M
Enterprise Value
238.21M
Income
-29.43M
Sales
0.00M
Book/sh
1.58
Cash/sh
1.56
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
22
IPO
Jun 28, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.86
P/C
1.87
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
128.41
Current Ratio
128.41
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.39
EPS next Y
-0.41
EPS next Q
-0.17
EPS this Y
-99.00%
EPS next Y
18.59%
EPS next 5Y
-16.72%
EPS past 3/5Y
18.28% 16.47%
Sales past 3/5Y
-32.07% -35.11%
EPS Y/Y TTM
-59.89%
Sales Y/Y TTM
-100.00%
EPS Q/Q
-58.09%
Sales Q/Q
-
Insider Own
20.20%
Insider Trans
0.00%
Inst Own
28.61%
Inst Trans
8.35%
ROA
-19.99%
ROE
-20.33%
ROIC
-10.72%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-5.02%
SMA50
1.03%
SMA200
46.32%
Trades
Shs Outstand
173.92M
Shs Float
138.97M
52W High
4.20 -30.24%
52W Low
0.91 221.97%
Volatility
4.11% 7.33%
ATR (14)
0.19
RSI (14)
45.65
Beta
1.47
Rel Volume
0.03
Avg Volume
443.98K
Volume
659
Perf Week
-9.57%
Perf Month
-0.34%
Perf Quarter
-5.79%
Perf Half Y
130.71%
Perf YTD
51.03%
Perf Year
9.33%
Perf 3Y
301.37%
Perf 5Y
-17.46%
Perf 10Y
-
Prev Close
3.02
Price
2.93
Change %
-2.98%
Consensus
Strong Buy
Avg. Price Target
$10.00
Implied Upside
+241.3%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 25, 2026Initiated
GGuggenheim
Buy$11+275.4%
Sep 22, 2026Initiated
CCantor Fitzgerald
Overweight
Sep 18, 2026Initiated
LLeerink Partners
Outperform$9+207.2%
Mar 22, 2021Initiated
AAegis Capital
Buy$12+309.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Germano Geno JDirectorMar 09 '26Buy1.3020,00026,00040,000Mar 11 08:30 AM
Ellis SeanDirectorMar 05 '26Buy1.2310,00012,300188,098Mar 09 08:30 AM
Rubin Steven DDirectorFeb 12 '26Buy1.495,0007,45015,000Feb 17 08:30 AM
Rubin Steven DDirectorFeb 09 '26Buy1.2010,00012,00010,000Feb 11 08:44 AM
Ellis SeanDirectorFeb 09 '26Buy1.2418,00022,320178,098Feb 11 08:42 AM
Toledano Miranda JayneChief Executive OfficerDec 29 '25Buy1.8111,00019,912426,575Dec 30 06:01 AM
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH(1-34), GLP-1 and GLP-2. The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
CEO & DirectorMs. Miranda J. Toledano M.B.A.
Ph.D.Dr. Hillel Galitzer M.B.A.
Chief of Research & DevelopmentDr. Gregory Burshtein Ph.D.
Chief Financial OfficerMs. Dana Yaacov-Garbeli CPA
Chief Clinical AdvisorDr. Rachel B. Wagman